Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Biotechnology & Medical Research

Market Closed - Nasdaq 21:30:00 21/06/2024 BST 5-day change 1st Jan Change
0.6124 USD -1.84% Intraday chart for Quoin Pharmaceuticals, Ltd. -10.75% -87.51%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Certain Options of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 6-JUN-2024. CI
Certain Warrants of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 6-JUN-2024. CI
Certain American Depositary Shares of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 6-JUN-2024. CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating MT
Quoin Pharmaceuticals Seeks M&A Opportunities CI
Transcript : Quoin Pharmaceuticals, Ltd., Q4 2023 Earnings Call, Mar 14, 2024
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
ADRs Close Higher; Dada Nexus Ltd. Climbs 30% DJ
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3% DJ
Top Midday Decliners MT
Quoin Pharmaceuticals Prices $6.5 Million Public Offering; Shares Fall MT
Top Premarket Decliners MT
Top Midday Gainers MT
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial DJ
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies CI
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product CI
Quoin Pharmaceuticals, Ltd. announced that it expects to receive $8 million in funding from Alumni Capital LP CI
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Quoin Pharmaceuticals, Ltd., Q3 2023 Earnings Call, Nov 09, 2023
Quoin Pharmaceuticals, Ltd. Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome CI
Quoin Pharmaceuticals Ltd. Enters into an Exclusive License and Distribution Agreement with Farma Mondo SA CI
Quoin Pharmaceuticals Limited Seeks M&A CI
Transcript : Quoin Pharmaceuticals, Ltd., Q2 2023 Earnings Call, Aug 03, 2023
Chart Quoin Pharmaceuticals, Ltd.
More charts
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.6124 USD
Average target price
5.483 USD
Spread / Average Target
+795.38%
Consensus
  1. Stock Market
  2. Equities
  3. QNRX Stock
  4. News Quoin Pharmaceuticals, Ltd.
  5. Quoin Pharmaceuticals Prices $6.5 Million Public Offering; Shares Fall